[go: up one dir, main page]

MA48730A - Compositions et méthodes de traitement de synucléinopathies - Google Patents

Compositions et méthodes de traitement de synucléinopathies

Info

Publication number
MA48730A
MA48730A MA048730A MA48730A MA48730A MA 48730 A MA48730 A MA 48730A MA 048730 A MA048730 A MA 048730A MA 48730 A MA48730 A MA 48730A MA 48730 A MA48730 A MA 48730A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
compositions
treatment
methods
Prior art date
Application number
MA048730A
Other languages
English (en)
Inventor
Kumar Kandadi Muralidharan
Natasha Penner
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA48730A publication Critical patent/MA48730A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA048730A 2017-03-31 2018-03-30 Compositions et méthodes de traitement de synucléinopathies MA48730A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US201762528790P 2017-07-05 2017-07-05

Publications (1)

Publication Number Publication Date
MA48730A true MA48730A (fr) 2020-04-08

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048730A MA48730A (fr) 2017-03-31 2018-03-30 Compositions et méthodes de traitement de synucléinopathies

Country Status (13)

Country Link
US (1) US20200377579A1 (fr)
EP (1) EP3630815A1 (fr)
JP (1) JP2020512368A (fr)
KR (1) KR20200026789A (fr)
CN (1) CN110997715A (fr)
AU (1) AU2018242626A1 (fr)
BR (1) BR112019020335A2 (fr)
CA (1) CA3058304A1 (fr)
IL (1) IL269637A (fr)
JO (1) JOP20190227A1 (fr)
MA (1) MA48730A (fr)
SG (1) SG11201908672WA (fr)
WO (1) WO2018178950A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JP2021502955A (ja) * 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EA202190807A1 (ru) * 2018-10-19 2021-08-06 Янссен Вэксинс Энд Превеншн Б.В. Антитела к синуклеину
WO2021110995A1 (fr) * 2019-12-04 2021-06-10 Ac Immune Sa Nouvelles molécules de thérapie et de diagnostic
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
KR20230086674A (ko) 2020-09-10 2023-06-15 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료
MX2024002970A (es) 2021-09-16 2024-03-27 H Lundbeck As Composiciones y metodos para el tratamiento de sinucleinopatias.
CN120882734A (zh) * 2023-02-06 2025-10-31 创新生物肽有限公司 用于治疗神经紊乱的肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
EA030777B9 (ru) * 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн

Also Published As

Publication number Publication date
US20200377579A1 (en) 2020-12-03
BR112019020335A2 (pt) 2020-04-28
JOP20190227A1 (ar) 2019-09-30
SG11201908672WA (en) 2019-10-30
EP3630815A1 (fr) 2020-04-08
JP2020512368A (ja) 2020-04-23
KR20200026789A (ko) 2020-03-11
CA3058304A1 (fr) 2018-10-04
CN110997715A (zh) 2020-04-10
AU2018242626A1 (en) 2019-10-10
IL269637A (en) 2019-11-28
WO2018178950A1 (fr) 2018-10-04

Similar Documents

Publication Publication Date Title
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA46102A (fr) Composés de tétracycline et méthodes de traitement
FR24C1025I1 (fr) Compositions et méthodes de traitement de l'anémie
EP3687981A4 (fr) Compositions et méthodes de traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3397149A4 (fr) Cartographie et traitement de tissu
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3442515A4 (fr) Préparation liposomale et méthodes de traitement
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
MA52790A (fr) Compositions et méthodes de traitement de la thrombopénie immune
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3458159A4 (fr) Compositions et méthodes de prévention et de traitement myopathies mitochondriales
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3373962A4 (fr) Compositions et méthodes de traitement de maladies auto-immunes et de cancers
EP3658142A4 (fr) Compositions et méthodes de traitement de la galactosémie
EP3713583A4 (fr) Méthodes et compositions pour le traitement de la peau
EP3691649A4 (fr) Compositions et méthodes de traitement des plaies
EP3313186A4 (fr) Combinaison d'inhibiteurs de lpt-723 et de point de contrôle immunitaire et méthodes de traitement
EP3298141A4 (fr) Compositions et méthodes de traitement du cancer
EP3386507A4 (fr) Méthodes et compositions de traitement des ulcères gastriques